Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Rituximab in paediatric onset multiple sclerosis: a case series.
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Mitoxantrone-induced suicidal erythrocyte death.
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
Selective inhibition of CCR7- TEM cells activation by a novel peptide targeting Kv1.3 in a rat EAE model.
FDA denies Teva Copaxone generic trials petition
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Pathological mechanisms in progressive multiple sclerosis.
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]

Pages